Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.

被引：1

作者：

Rodon, Jordi ^{[1
]}

Juric, Dejan ^{[2
]}

Gonzalez-Angulo, Ana-Maria ^{[3
]}

Bendell, Johanna ^{[4
]}

Berlin, Jordan ^{[5
]}

Bootle, Douglas ^{[6
]}

Gravelin, Kathlene ^{[7
]}

Huang, Alan ^{[7
]}

Derti, Adnan ^{[7
]}

Lehar, Joseph ^{[7
]}

Wuerthner, Jens ^{[6
]}

Boehm, Markus ^{[6
]}

van Allen, Eliezer ^{[8
]}

Wagle, Nikhil ^{[8
]}

Garraway, Levi A. ^{[8
]}

Yelensky, Roman ^{[9
]}

Stephens, Philip J. ^{[9
]}

Miller, Vincent A. ^{[9
]}

Schlegel, Robert ^{[7
]}

Quadt, Cornelia ^{[6
]}

Baselga, Jose ^{[10
]}

机构：

[1] Vail dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Vanderbilt Canc Ctr, Nashville, TN USA

[6] Novartis Pharma AG, Oncol Translat Med, Basel, Switzerland

[7] NIBR Inc, Oncol Translat Med, Cambridge, MA USA

[8] Broad Inst, Cambridge, MA USA

[9] Fdn Med Inc, Cambridge, MA USA

[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

CANCER RESEARCH | 2013年 / 73卷 / 08期

关键词：

D O I：

10.1158/1538-7445.AM2013-LB-65

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB65

引用

页数：2

共 44 条

[21] The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models
Noelting, Svenja
Rentsch, Jakob
Freitag, Helma
Detjen, Katharina
Briest, Franziska
Moebs, Markus
Weissmann, Victoria
Siegmund, Britta
Auernhammer, Christoph J.
Prada, Elke Tatjana Aristizabal
Lauseker, Michael
Grossman, Ashley
Exner, Samantha
Fischer, Christian
Groetzinger, Carsten
Schrader, Joerg
Grabowski, Patricia
PLOS ONE, 2017, 12 (08):
[22] Synergistic suppression of triple negative breast cancer with the combination of PI3K inhibitor (alpelisib, BYL719) and CDK inhibitor (ribociclib, LEE011)
Yuan, Y.
Mortimer, J.
Xing, Q.
Yan, J.
Wen, W.
Han, E.
Yim, J. H.
CANCER RESEARCH, 2017, 77
[23] Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Fritsch, Christine
Huang, Alan
Chatenay-Rivauday, Christian
Schnell, Christian
Reddy, Anupama
Liu, Manway
Kauffmann, Audrey
Guthy, Daniel
Erdmann, Dirk
De Pover, Alain
Furet, Pascal
Gao, Hui
Ferretti, Stephane
Wang, Youzhen
Trappe, Joerg
Brachmann, Saskia M.
Maira, Sauveur-Michel
Wilson, Christopher
Boehm, Markus
Garcia-Echeverria, Carlos
Chene, Patrick
Wiesmann, Marion
Cozens, Robert
Lehar, Joseph
Schlegel, Robert
Caravatti, Giorgio
Hofmann, Francesco
Sellers, William R.
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (05) : 1117 - 1129
[24] HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma
Meister, Kara S.
Godse, Neal R.
Khan, Nayel, I
Hedberg, Matthew L.
Kemp, Carolyn
Kulkarni, Sucheta
Alvarado, Diego
LaVallee, Theresa
Kim, Seungwon
Grandis, Jennifer R.
Duvvuri, Umamaheswar
SCIENTIFIC REPORTS, 2019, 9 (1)
[25] Phase Ib/II study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)
Razak, Albiruni R. A.
Ahn, Myung-Ju
Yen, Chia-Jui
Solomon, Benjamin J.
Lee, Se-Hoon
Wang, Hung-Ming
Munster, Pamela N.
L-Van Herpen, Carla M.
Gilbert, Jill
Pal, Rupam Ranjan
Blumenstein, Lars
Gomez-Carrillo, Belen
Coughlin, Christina Marie
Lim, Wan-Teck
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[26] Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
Shah, Payal D.
Moynahan, Mary Ellen
Modi, Shanu
Caravella, Betty Ann
Datko, Farrah M.
Zamora, Stephen
Comen, Elizabeth
Gilewski, Theresa
Sugarman, Steven M.
D'Andrea, Gabriella
Lake, Diana E.
Goldfarb, Shari B.
Patil, Sujata
Covey, Anne
Berger, Michael F.
Lacouture, Mario E.
Norton, Larry
Hudis, Clifford A.
Baselga, Jose
Chandarlapaty, Sarat
Dickler, Maura N.
CANCER RESEARCH, 2015, 75
[27] Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab
Cao, Z. Alexander
Pinzon-Ortiz, Maria
Chen, Yan
Li, Xiaoyan
Beltran, Pedro J.
Gansert, Jennifer
Peters, Malte
Schlegel, Robert
Schumacher, Karl M.
Huang, Alan
CANCER RESEARCH, 2014, 74 (19)
[28] Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC) using 3D cell culture system
Cheong, Hio Teng
Wong, Chi Hang
Hui, Connie Wun Chun
Chan, Anthony Tak Cheung
Ma, Brigette Buig Yue
CANCER RESEARCH, 2014, 74 (19)
[29] Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant
Jacquemetton, Julien
Kassem, Loay
Poulard, Coralie
Dahmani, Ahmed
De Plater, Ludmilla
Montaudon, Elodie
Sourd, Laura
Morisset, Ludivine
El Botty, Rania
Chateau-Joubert, Sophie
Vacher, Sophie
Bieche, Ivan
Treilleux, Isabelle
Tredan, Olivier
Marangoni, Elisabetta
Le Romancer, Muriel
BREAST CANCER RESEARCH, 2021, 23 (01)
[30] Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant
Julien Jacquemetton
Loay Kassem
Coralie Poulard
Ahmed Dahmani
Ludmilla De Plater
Elodie Montaudon
Laura Sourd
Ludivine Morisset
Rania El Botty
Sophie Chateau-Joubert
Sophie Vacher
Ivan Bièche
Isabelle Treilleux
Olivier Trédan
Elisabetta Marangoni
Muriel Le Romancer
Breast Cancer Research, 23

← 1 2 3 4 5 →